Keywords: Diagnosis/Prediction, Machine Learning/Artificial Intelligence
Motivation: Predicting liver cancer treatment outcomes, especially for combination therapies, is challenging due to the limited sensitivity of conventional MRI. This study uses a Vision Transformer model to enhance response specificity.
Goal(s): To develop and validate an MRI-based classification model that accurately differentiates outcomes across control, single (NK or Sorafenib), and combination (NK + Sorafenib) treatments in an HCC rat model.
Approach: Multi-parametric MRI data from a Buffalo rat model with liver-implanted McA-RH7777 cells were analyzed using a ViT model to classify treatment outcomes.
Results: The model achieved an accuracy of 79.4%, sensitivity of 78.1%, specificity of 79.5%, and an AUROC of 90.1%
Impact: This study showcases the potential of ViT-based MRI analysis in distinguishing HCC treatment outcomes, enabling more precise combination therapy selection and advancing personalized care for improved patient outcomes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords